Brief: Silo Pharma Initiates Pharmacokinetic And Tolerability Study For Sp-26 Targeting Chronic Pain And Fibromyalgia
18/12/2024 12:58
Dec 18 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA INITIATES PHARMACOKINETIC AND TOLERABILITY
STUDY FOR
SP-26 TARGETING CHRONIC PAIN AND FIBROMYALGIA
Source text: ID:nGNX4xg0Yy
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement